In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data
- PMID: 37223825
- PMCID: PMC10202112
- DOI: 10.2147/CEOR.S405079
In-Hospital Outcomes of Heart Failure Patients with Valvular Heart Disease: Insights from Real-World Claims Data
Abstract
Purpose: Heart failure (HF) is a serious public health burden that is rapidly increasing in the aging population. Valvular heart disease (VHD) is a known etiology of heart failure (HF); however, the impact of VHD on outcomes of patients with HF has not been well-studied in Japan. This study aimed to determine the rates of VHD in Japanese patients admitted for HF and explore associations of VHD with in-hospital outcomes through a claim-based analysis.
Patients and methods: We analyzed claims data from 86,763 HF hospitalizations (January 2017 through December 2019) from the Medical Data Vision database. Common etiologies of HF were examined, then hospitalizations were categorized into those with VHD and those without. Covariate-adjusted models were used to explore the association of VHD with in-hospital mortality, length of stay, and medical cost.
Results: Of 86,763 hospitalizations for HF, 13,183 had VHD and 73,580 did not. VHD was the second most frequent etiology of HF (15.2%). The most frequent type of VHD was mitral regurgitation (36.4% of all hospitalizations with VHD), followed by aortic stenosis (33.7%) and aortic regurgitation (16.4%). There was no significant difference in in-hospital mortality between hospitalizations with VHD vs those without (9.0% vs 8.9%; odds ratio [95% CI]: 1.01 [0.95-1.08]; p=0.723). Hospitalizations with VHD were associated with significantly longer length of stay (26.1 vs 24.8 days; incident rate ratio [95% CI]: 1.05 [1.03-1.07]; p<0.001) and higher medical costs (1536 vs 1195 thousand yen; rate ratio [95% CI]: 1.29 [1.25-1.32]; p<0.001).
Conclusion: VHD was a frequent etiology of HF that was associated with significant medical resource use. Future studies are needed to investigate whether timely VHD treatment could reduce HF progression and its associated healthcare resource utilization.
Keywords: etiology; hospital claims; length of stay; medical costs; medical data vision; mortality.
© 2023 Izumi et al.
Conflict of interest statement
CI received consult fees from Abbott Japan LLC and Edwards Lifesciences Limited. RM and KY are employees of Edwards Lifesciences Limited. SM is an employee of Edwards Lifesciences Corporation and has Edwards stock. KI and TT are employee of Milliman Inc., which has received consult fees from Edwards Lifesciences Limited. AI received research fund from Edwards Lifesciences Limited and Boston Scientific Inc.; consult fees and lecture fees from Abbott Inc., GSK Japan Inc., Medtronic Inc., MSD Inc., Moderna Japan Inc., Pfizer Japan Inc., Sanofi-Pasteur Inc., Novartis Pharma K.K., AbbVie GK, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Inc., Novo Nordisk Pharma Inc., Eisai Inc., Beckton Dickinson and Company, Maruho Co. Ltd., Ono Pharmaceutical Inc., Sato Pharmaceutical Inc., Sumitomo Dainippon Pharma Inc., and Eli Lilly Japan K.K., outside the submitted work; research grants from Taiho Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Beckton & Dickinson Inc., CSL Behring Japan Inc., Gilead Science K.K., Takeda Pharmaceutical Inc., Boston Scientific Japan Inc., DeSC Healthcare Inc., Otsuka Pharmaceutical K.K., Varian Medical systems and Intuitive Surgical GK., outside the submitted work. The authors report no other conflicts of interest in this work.
Figures





Similar articles
-
Prevalence, incidence, patient characteristics, and treatment trends of valvular heart disease using the national database of health insurance claims of Japan.J Med Econ. 2025 Dec;28(1):405-412. doi: 10.1080/13696998.2025.2474885. Epub 2025 Mar 13. J Med Econ. 2025. PMID: 40022642
-
Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study.JACC Asia. 2022 Apr 12;2(3):354-365. doi: 10.1016/j.jacasi.2021.11.013. eCollection 2022 Jun. JACC Asia. 2022. PMID: 36338396 Free PMC article.
-
Profiles of hospitalized patients with valvular heart disease: Experience of a tertiary center.Rev Port Cardiol (Engl Ed). 2018 Dec;37(12):991-998. doi: 10.1016/j.repc.2018.02.012. Epub 2018 Dec 13. Rev Port Cardiol (Engl Ed). 2018. PMID: 30554887 English, Portuguese.
-
Different heart failure phenotypes of valvular heart disease: the role of mitochondrial dysfunction.Front Cardiovasc Med. 2023 May 19;10:1135938. doi: 10.3389/fcvm.2023.1135938. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37273869 Free PMC article. Review.
-
Imaging of Valvular Heart Disease in Heart Failure.Card Fail Rev. 2018 Aug;4(2):78-86. doi: 10.15420/cfr.2018.16.1. Card Fail Rev. 2018. PMID: 30206481 Free PMC article. Review.
Cited by
-
Global epidemiology of heart failure.Nat Rev Cardiol. 2024 Oct;21(10):717-734. doi: 10.1038/s41569-024-01046-6. Epub 2024 Jun 26. Nat Rev Cardiol. 2024. PMID: 38926611 Review.
-
The Caregiving Burden of Japan's Older Population Living With Valvular Heart Disease.Sage Open Aging. 2025 Jun 25;11:30495334251347099. doi: 10.1177/30495334251347099. eCollection 2025 Jan-Dec. Sage Open Aging. 2025. PMID: 40611865 Free PMC article.
-
Contemporary Profile and In-Hospital Outcomes of Decompensated Heart Failure in a Semi-Rural Setting in Cameroon: The Buea Heart Study.Glob Heart. 2025 Jun 23;20(1):56. doi: 10.5334/gh.1442. eCollection 2025. Glob Heart. 2025. PMID: 40585393 Free PMC article.
-
Incidence and Healthcare Resource Utilization Among Patients with Hypertrophic Cardiomyopathy Hospitalized for Heart Failure in Japan.Cardiol Ther. 2025 Jul 19. doi: 10.1007/s40119-025-00427-3. Online ahead of print. Cardiol Ther. 2025. PMID: 40682613
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous